| Revision as of 17:56, 4 March 2007 edit83.41.240.55 (talk)No edit summary← Previous edit | Revision as of 17:57, 4 March 2007 edit undo83.41.240.55 (talk)No edit summaryNext edit → | ||
| Line 1: | Line 1: | ||
| '''Noradrenergic and specific serotonergic antidepressants''' (abbreviated: '''NaSSAs''') are a relatively new class of ]s. They are thought to act by ] autoreceptor and heteroreceptor antagonism combined with specific serotonergic antagonism. This results in increases in both noradrenergic and specific serotonergic transmission. | '''Noradrenergic and specific serotonergic antidepressants''' (abbreviated: '''NaSSAs''') are a relatively new class of ]s. They are thought to act by ] autoreceptor and heteroreceptor antagonism combined with specific ] antagonism. This results in increases in both noradrenergic and specific serotonergic transmission. | ||
| Examples of NaSSAs include: | Examples of NaSSAs include: | ||
Revision as of 17:57, 4 March 2007
Noradrenergic and specific serotonergic antidepressants (abbreviated: NaSSAs) are a relatively new class of antidepressants. They are thought to act by noradrenergic autoreceptor and heteroreceptor antagonism combined with specific serotonergic antagonism. This results in increases in both noradrenergic and specific serotonergic transmission.
Examples of NaSSAs include:
- Mirtazapine (Remeron®, Zispin®, Avanza®, Norset®, Remergil®)
NaSSAs are said to have fewer side effects than tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) while being equally effective. In particular, it is said that the sexual dysfunction that is a relatively common side effect of SSRIs occurs significantly less often during treatment with NaSSAs.
See also
External links
 | This medical treatment–related article is a stub. You can help Misplaced Pages by expanding it. |
..
Categories: